Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Truist Financial

Stock analysts at Truist Financial assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Monday. The firm set a “buy” rating and a $798.00 price target on the biopharmaceutical company’s stock. Truist Financial’s price objective suggests a potential upside of 3.86% from the stock’s current price.

Several other research analysts also recently commented on the company. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. HSBC started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $255.00 price target on the stock. Finally, Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $757.91.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $12.44 during mid-day trading on Monday, hitting $768.34. 310,177 shares of the company were exchanged, compared to its average volume of 1,101,377. The company has a market capitalization of $80.75 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The business has a fifty day moving average of $615.29 and a 200 day moving average of $575.83. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $800.99. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the prior year, the firm earned $12.46 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Cove Private Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 20 shares during the period. Marino Stram & Associates LLC increased its stake in shares of Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 20 shares during the last quarter. CoreCap Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 20 shares during the period. Activest Wealth Management boosted its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Finally, Strait & Sound Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 3.5% during the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 21 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.